Abstracts tagged "Bone density"

Abstract Number: 2110 • ACR Convergence 2025
Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Edgar Wiebe¹, Kerstin Rubarth², Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche⁴, Gerhard Krönke⁵, Andriko Palmowski⁴ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures due to systemic inflammation and glucocorticoid (GC)…
Abstract Number: 0341 • ACR Convergence 2025
Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Daniel Ramos Castro¹, SAMUEL LEAL², ELENA GRAU GARCIA³, Pablo Muñoz-Martínez⁴, Laura Mas Sanchez⁵, Alba Maria Torrat Noves⁶, Belen Villanueva Manes⁷, Iago Alcántara Álvarez⁸, Andres perez Hurtado⁹, Miguel Simeo Vinaixa⁹ and José Andrés Román Ivorra¹⁰, ¹Hospital Universitari i Politecnic La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Hospital Universitari i Politecnic La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital La Fe, València, Spain, ⁸Hospital Universitari i Politénic La Fe, València, Spain, ⁹Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is the most common bone metabolism disorder in developed countries. It increases the risk of fragility fractures, impairing quality of life, increasing disability,…
Abstract Number: 2109 • ACR Convergence 2025
Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Edgar Wiebe¹, Lien Meerkatt², Andriko Palmowski³, Zhivana Boyadzhieva⁴, Kerstin Rubarth⁵, Sandra Hermann¹, Burkhard Muche³, Gerhard Krönke⁶ and FRANK BUTTGEREIT⁷, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁷Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Individuals with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are at increased risk for osteoporosis and fragility fractures due to long-term glucocorticoid (GC)…
Abstract Number: 0340 • ACR Convergence 2025
Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Chern Lee Choy¹, Hamzah Amin² and marwan Bukhari³, ¹University Hospitals of Morecambe Bay NHS Foundation Trust, Barrow-In-Furness, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: It is well recognized that inflammatory bowel disease (IBD) is associated with osteoporosis and fragility fractures, likely due to multiple factors, including systemic inflammation,…
Abstract Number: 1066 • ACR Convergence 2024
Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Krista Topalsky¹, Lee Arphai², Mary Ellen Amos², Amanda Mertz², Christopher Blum³, Timothy Godbey², Lori Leonard², Maya Mattar⁴, Elizabeth Cable² and Robert Wenzell², ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²Cleveland VA Medical Center, Cleveland, OH, ³Cleveland VA Medical Center, Cleveland, ⁴Louis Stokes VA medical Center, Mayfield Heights, OH
Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
Abstract Number: 2226 • ACR Convergence 2024
Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis
John Chen¹, Malini Chandra², Laura Carbone³, John Schousboe⁴, Elisha Garcia² and Joan Lo², ¹Kaiser Permanente Oakland Medical Center, Oakland, CA, ²Kaiser Permanente, Oakland, CA, ³Augusta University, Augusta, GA, ⁴University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) and osteoporosis are both chronic, potentially debilitating conditions that frequently co-occur, affecting millions of people annually. Among those with osteoporosis, RA…
Abstract Number: 1084 • ACR Convergence 2024
Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout
Karla Miller¹, grant Cannon¹, Kyle Register², Nadia Grant² and Naomi Schlesinger², ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Controversy exists surrounding the association of gout with osteoporosis diagnosis or incident fragility fractures. Dual-Energy X-Ray Absorptiometry (DXA) scan is the gold standard for…
Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakow Medical Centre, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
Abstract Number: 1616 • ACR Convergence 2024
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Gaston Ariel Ghio¹, Marta Domínguez-Álvaro², Ricardo Blanco-Alonso³, Santos Castañeda⁴, Iñigo Hernández-Rodríguez⁵, Elisa Fernández-Fernández:⁶, Maite Silva-Diaz⁷, Joaquin María Belzunegui:⁸, Clara Moriano⁹, Julio Sánchez-Martín¹⁰, Javier Narvaez-García¹¹, Eva Galindez¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuán¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota L Iñiguez:¹⁷, Alicia García Dorta¹⁸, Clara Molina Almela¹⁹ and María Alcalde Villar:²⁰, and ARTESER Project Collaborative Group, ¹Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁷Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸H de Donostia, Donostia-San Sebasti, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Hospital Universitario de Cabueñes, Bilbao, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁸Rheumatologist, La Laguna, Spain, ¹⁹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁰Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
Abstract Number: 2114 • ACR Convergence 2024
CT and DXA Bone Fragility Evaluation After Bariatric Surgery
Marine FAUNY¹, Marion Halin², Edem Allado², Laurent Brunaud², Claire Nomine Criqui², Eliane Albuisson², Isabelle Chary-Valckenaere³, Damien Loeuille⁴ and Didier Quilliot², ¹CH TOUL, Toul, Lorraine, France, ²Nancy University Hospital, Vandoeuvre, Lorraine, France, ³Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁴Phd, Nancy Vandoeuvre, Lorraine, France
Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…
Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Yen-An Chang¹ and Ming‑Han Chen², ¹Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
Abstract Number: 2119 • ACR Convergence 2024
IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
Chloe Heiting¹, Donald McMahon¹, Douglas Mintz¹, Weijia Yuan¹, Insa Mannstadt¹, Linda A Russell¹, Emily Stein¹, Dalit Ashany² and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Scarsdale, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
Abstract Number: 2120 • ACR Convergence 2024
EvaluationofBone Mineral Densityand Trabecular Bone Score in JuvenileSystemicLupusErythematosusPatientsUsing Dual-Energy X-rayAbsorptiometry
BEATRIZ ROSA¹, Melissa Fraga¹, Erica Barbosa¹, Jade Dib Fernandez², Marcelo Pinheiro³ and Maria Teresa Terreri⁴, ¹Universidade Federal de São Paulo, São Paulo, SP, Brazil, ²UNIFESP-EPM, São Paulo, SP, Brazil, ³UNIFESP/ EPM, São Paulo, SP, Brazil, ⁴UNIFESP, São Paulo, SP, Brazil
Background/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a multisystem inflammatory disease associated with bone mass loss. This loss can be evaluated by using the bone…
Abstract Number: 2125 • ACR Convergence 2024
Strengthening Fracture Risk Prediction in Rheumatoid Arthritis: Integrating a Self-report Sarcopenia Screening Tool (SARC-F) and Fracture Risk Assessment Tool (FRAX) Scores
Ana Rodriguez-Flores¹, Ana Cecilia Bardan-Inchaustegui², Mara Ponce², Galilea Rodriguez³, Anahí Carrazco Chapa⁴, Valeria Monserrat De Hoyos-Perez⁵, Gilberto J Cervantes Charles⁵, Alma Damian Peñaloza⁵, Cinthia Maribel Cortez Lopez⁵, CASSANDRA SKINNER TAYLOR⁶, Roberto Negrete Lopez⁵, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, ⁴Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, ⁵Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁶HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of fractures due to factors such as chronic inflammation, use of glucocorticoids, and reduced muscle mass.…
Abstract Number: 2126 • ACR Convergence 2024
Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Carmen Gomez Vaquero¹, Marta Domínguez-Álvaro², Daniel Seoane-Mato³, Pilar Peris⁴, Santos Castañeda⁵, Eduardo Kanterewicz Binstock⁶, Ramon Mazzucchelli⁷, Luis Arboleya⁸, Miguel Bernad⁹, Antonio Alvarez-Cienfuegos¹⁰, Blanca Correa¹¹, Luis-Maria Jimenez-Liñan¹², Carmen Mateo-Pascual¹³, Mª Mercedes Molina del Rio¹⁴, Mercedes Retamal-Ortiz¹⁵, Aida Fatima Lopez-Laguna¹⁶, Ruth Molera-Valero¹⁷, Sara Alvar-Pariente¹⁸, Antonio Pascual¹⁹, Adolfo Arias-Senso²⁰, Nuria Perez-Gutierrez²¹, Soledad Garcia-Frias²², David Bouza-Alvarez²³, Susana Sostres²⁴, Daniel Suarez-Hernandez²⁵, Ana Zamora-Casal²⁶, Cristina Garcia-Ramirez²⁷ and Enrique González-Dávila²⁸, and OsteoSER Project Collaborative Group, ¹Hospital Universitari de Bellvitge, 08907 L'Hospitalet, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Sociedad Española de Reumatología, Madrid, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Universitari de Vic (Consorci Hospitalari de Vic), Barcelona, Spain, ⁷Hospital Universitario Fundacion Alcorcon, Madrid, Spain, ⁸Hospital Universitario Central de Asturias, Oviedo, Spain, ⁹Hospital Universitario La Paz, Madrid, Spain, ¹⁰Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain, ¹¹Clínica Sanz y Correa, A Coruña, Spain, ¹²Hospital Don Benito-Villanueva, Don Benito, Spain, ¹³Centro de Salud Fuencarral, distrito Fuencarral-El Pardo, Madrid, Spain, ¹⁴Centro de Atención Primaria Viladecans Montbaig, Sant Climent de Llobregat, Spain, ¹⁵Centro de Salud Don Benito Oeste, Don Benito, Spain, ¹⁶Centro de Salud El Molar, El Molar, Spain, ¹⁷Centro de Salud Orihuela 1-El Rabaloche, Orihuela, Spain, ¹⁸Centro de Salud Malpica, Malpica, Spain, ¹⁹Centro de salud Ronda-Norte y Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁰Centro de Salud de Santa Amalia, Santa Amalia, Spain, ²¹Centro de Atención Primaria Ramona Via i Pros, El Prat de Llobregat, Spain, ²²Centro de Salud de Cortes de la Frontera, Cortes de la Frontera, Spain, ²³Centro de Salud Elviña Mesoiro, A Coruña, Spain, ²⁴Centro de Atención Primaria Cap 17 de setembre, El Prat de Llobregat, Spain, ²⁵Centro de Salud de Benejuzar, Benezujar, Spain, ²⁶Centro de Salud Os Mallos, A Coruña, Spain, ²⁷Centro de Salud Ronda-Sur Santa Bárbara, Ronda, Spain, ²⁸Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain
Background/Purpose: The bone mineral density (BMD) reference data for the Spanish population comes from the study Multicentre Research Project on Osteoporosis (MPRO), concluded in 1989.Our…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].